REFERENCES
- Fletcher, A. P., Alkjaersig, N. and Sherry, S.: Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J Clin Invest 41:896–916 (April) 1962.
- Lieberman, J.: Current appraisal of thrombolytic therapy. Calif Med 99:301–307 (November) 1963.
- Pritchard, J. A. and Wright, M. R.: Pathogenesis of hypofibrinogenemia in placental abruption. New Eng J Med 261:218–222 (July 30) 1959.
- Beller, F. K., Douglas, G. W., Debrovner, C. H. and Robinson, R.: The fibrinolytic system in amniotic fluid embolism. Amer J Obstet Gynec 87: 48–55 (September 1) 1963.
- Alkjaersig, N., Fletcher, A. P. and Sherry, S.: The mechanism of clot dissolution by plasmin. J Clin Invest 38:1086–1095 (July) 1959.
- Todd, A. S.: Some topographical observations on fibrinolysis. J Clin Path 17:324–327 (May) 1964.
- Fletcher, A. P., Biederman, O., Moore, D., Alkjaersig, N. and Sherry, S.: Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: Its cause and consequences. J Clin Invest 43:681–695 (April) 1964.
- Sherry, S., Fletcher, A. P. and Alkjaersig, N.: Developments in fibrinolytic therapy for thromboembolic disease. Ann Intern Med 50:560, 1959.
- Sherry, S., Fletcher, A. P., Alkjaersig, N. and Sawyer, W. D.: Epsilon aminocaproic acid, “a potent anti-fibrinolytic agent.” Trans Ass Amer Physicians 72:62–70, 1959.